Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
BMC Cancer|February 18, 2011
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trialFrancesco Nuzzo, Alessandro Morabito, Adriano Gravina, et al.
Cancers|March 13, 2019
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) PatientsAnna Maria Rachiglio, Francesca Fenizia, Maria Carmela Piccirillo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2011
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trialCesare Gridelli, Ciro Gallo, Alessandro Morabito, et al.
Critical Reviews in Oncology/Hematology|December 28, 2007
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trialFrancesco Nuzzo, Alessandro Morabito, Ermelinda De Maio, et al.
Cancers|September 9, 2020
Immunotherapy in Small Cell Lung CancerGiovanna Esposito, Giuliano Palumbo, Guido Carillio, et al.
Expert Opinion on Drug Safety|May 14, 2020
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancerAnna Manzo, Guido Carillio, Agnese Montanino, et al.
BMC Cancer|September 3, 2008
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Plos One|August 6, 2010
Time spent for activation of non-profit studies in oncology in ItalyGianfranco De Feo, Simona Signoriello, Jane C Bryce, et al.
The Oncologist|February 20, 2024
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb TrialEmilio Bria, Floriana Morgillo, Marina Chiara Garassino, et al.
Journal of Translational Medicine|January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
BMC Cancer|February 18, 2011
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trialFrancesco Nuzzo, Alessandro Morabito, Adriano Gravina, et al.
Cancers|March 13, 2019
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) PatientsAnna Maria Rachiglio, Francesca Fenizia, Maria Carmela Piccirillo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2011
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trialCesare Gridelli, Ciro Gallo, Alessandro Morabito, et al.
Critical Reviews in Oncology/Hematology|December 28, 2007
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trialFrancesco Nuzzo, Alessandro Morabito, Ermelinda De Maio, et al.
Cancers|September 9, 2020
Immunotherapy in Small Cell Lung CancerGiovanna Esposito, Giuliano Palumbo, Guido Carillio, et al.
Expert Opinion on Drug Safety|May 14, 2020
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancerAnna Manzo, Guido Carillio, Agnese Montanino, et al.
BMC Cancer|September 3, 2008
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Plos One|August 6, 2010
Time spent for activation of non-profit studies in oncology in ItalyGianfranco De Feo, Simona Signoriello, Jane C Bryce, et al.
The Oncologist|February 20, 2024
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb TrialEmilio Bria, Floriana Morgillo, Marina Chiara Garassino, et al.
Journal of Translational Medicine|January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
Pageof 20